
Eleni Tiniakou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9455253/publications.pdf Version: 2024-02-01



FLENI TINIAKOU

#	Article	IF	CITATIONS
1	Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science, 2018, 359, 1156-1161.	6.0	608
2	Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy. New England Journal of Medicine, 2015, 373, 1680-1682.	13.9	138
3	Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2017, 52, 20-33.	2.9	97
4	Study of Tofacitinib in Refractory Dermatomyositis: An Openâ€Label Pilot Study of Ten Patients. Arthritis and Rheumatology, 2021, 73, 858-865.	2.9	93
5	Cytosolic 5′â€Nucleotidase 1A As a Target of Circulating Autoantibodies in Autoimmune Diseases. Arthritis Care and Research, 2016, 68, 66-71.	1.5	89
6	Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies. Neurology, 2018, 90, e2068-e2076.	1.5	76
7	More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology, 2017, 56, kew470.	0.9	67
8	Sex-specific environmental influences on the development of autoimmune diseases. Clinical Immunology, 2013, 149, 182-191.	1.4	44
9	Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. Neurology, 2019, 92, e1416-e1426.	1.5	36
10	More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies. Neurology, 2019, 93, e1768-e1777.	1.5	35
11	Myositis Autoantibodies: A Comparison of Results From the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot. Arthritis and Rheumatology, 2020, 72, 192-194.	2.9	34
12	Absence of anti–HMGâ€CoA reductase autoantibodies in severe selfâ€limited statinâ€related myopathy. Muscle and Nerve, 2016, 54, 142-144.	1.0	28
13	A North American Cohort of Anti‣AE Dermatomyositis: Clinical Phenotype, Testing, and Review of Cases. ACR Open Rheumatology, 2021, 3, 287-294.	0.9	28
14	Immune-mediated necrotizing myopathy associated with statins: history and recent developments. Current Opinion in Rheumatology, 2017, 29, 604-611.	2.0	25
15	Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Statinâ€Associated Immuneâ€Mediated Necrotizing Myopathy: A Case Series. Arthritis and Rheumatology, 2019, 71, 1723-1726.	2.9	25
16	Performance of the 2017 European Alliance of Associations for Rheumatology/American College of Rheumatology Classification Criteria for Idiopathic Inflammatory Myopathies in Patients With <scp>Myositis‧pecific</scp> Autoantibodies. Arthritis and Rheumatology, 2022, 74, 508-517.	2.9	24
17	Ultrasound can differentiate inclusion body myositis from disease mimics. Muscle and Nerve, 2020, 61, 783-788.	1.0	21
18	<p>Statin-Associated Autoimmune Myopathy: Current Perspectives</p> . Therapeutics and Clinical Risk Management, 2020, Volume 16, 483-492.	0.9	17

Eleni Tiniakou

#	Article	IF	CITATIONS
19	Risk Factors for Infection and Health Impacts of the Coronavirus Disease 2019 (COVID-19) Pandemic in People With Autoimmune Diseases. Clinical Infectious Diseases, 2022, 74, 427-436.	2.9	15
20	Longâ€ŧerm extension study of tofacitinib in refractory dermatomyositis. Arthritis and Rheumatology, 2022, 74, 371-372.	2.9	14
21	The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease. Respiratory Medicine, 2019, 150, 63-65.	1.3	13
22	The phenotype of myositis patients with anti-Ku autoantibodies. Seminars in Arthritis and Rheumatism, 2021, 51, 728-734.	1.6	13
23	Pattern of muscle involvement in inclusion body myositis: a sonographic study. Clinical and Experimental Rheumatology, 2018, 36, 996-1002.	0.4	13
24	Necrotizing myopathy caused by central hypothyroidism. Muscle and Nerve, 2015, 52, 152-153.	1.0	12
25	Muscle endurance deficits in myositis patients despite normal manual muscle testing scores. Muscle and Nerve, 2019, 59, 70-75.	1.0	12
26	Definition of Naturally Processed Peptides Reveals Convergent Presentation of Autoantigenic Topoisomerase I Epitopes in Scleroderma. Arthritis and Rheumatology, 2020, 72, 1375-1384.	2.9	12
27	Therapeutic options for cutaneous polyarteritis nodosa: a systematic review. Rheumatology, 2021, 60, 4039-4047.	0.9	12
28	Borrelia burgdorferi-Induced Changes in the Class II Self-Immunopeptidome Displayed on HLA-DR Molecules Expressed by Dendritic Cells. Frontiers in Medicine, 2020, 7, 568.	1.2	9
29	Therapeutic Management of Immune-Mediated Necrotizing Myositis. Current Treatment Options in Rheumatology, 2021, 7, 150-160.	0.6	9
30	Clinical and histopathological features of myositis in systemic lupus erythematosus. Lupus Science and Medicine, 2022, 9, e000635.	1.1	9
31	Sonographic findings from inflammatory arthritis due to antisynthetase syndrome. Clinical Rheumatology, 2019, 38, 1477-1483.	1.0	8
32	Insights into origins and specificities of autoantibodies in systemic sclerosis. Current Opinion in Rheumatology, 2021, 33, 486-494.	2.0	7
33	Granzyme B Induces IRF-3 Phosphorylation through a Perforin-Independent Proteolysis-Dependent Signaling Cascade without Inducing Cell Death. Journal of Immunology, 2021, 206, 335-344.	0.4	6
34	<scp>Anti ortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis. Arthritis and Rheumatology, 2022, 74, 358-364.	2.9	6
35	Lipid-lowering Therapies in Myositis. Current Rheumatology Reports, 2020, 22, 70.	2.1	3
36	Rheumatoid Pachymeningitis: A Rare Complication of Rheumatoid Arthritis. Journal of Rheumatology, 2018, 45, 1325-1326.	1.0	2

Eleni Tiniakou

#	Article	IF	CITATIONS
37	Microscopic Colitis: Is it an Allergic Phenomenon?. American Journal of Gastroenterology, 2012, 107, S205.	0.2	1
38	Timing Of Antibiotic Administration And Outcomes Of Patients With Nosocomial Sepsis. , 2011, , .		0
39	FRI0284â€Anti-Srp-Associated Autoimmune Myopathy: Younger Age at Onset Is Associated with More Severe Disease and Worse Outcome. Annals of the Rheumatic Diseases, 2016, 75, 538.1-538.	0.5	0
40	FRI0273â€Slow Recovery of Muscle Strength in Young Anti-HMG-COA Reductase Positive Myopathy Patients. Annals of the Rheumatic Diseases, 2016, 75, 534.1-534.	0.5	0
41	OP0038â€Myositis autoantibodies outperform clinical subgroup classification in predicting muscle weakness in myositis patients. , 2017, , .		0
42	06.15â€Naturally processed topoisomerase i peptides presented by dendritic cells identify immunodominant t cell epitopes in systemic sclerosis. , 2017, , .		0